Summit Therapeutics Inc. (SMMT)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Reclassification of unrealized loss on short-term investments to other expense, net | - | - | ||
| Unrealized loss on short-term investments | - | 346 | ||
| Foreign currency translation adjustments | -189 | -155 | ||
| Other operating (expense) income, net | - | -264 | ||
| Operating loss | - | -58,378 | ||
| Research and development | 208,021 | 37,724 | ||
| General and administrative | 360,416 | 20,390 | ||
| Acquired in-process research and development expense | - | - | ||
| Total operating expenses | 568,437 | 58,114 | ||
| Other income, net | 2,729 | 2,124 | ||
| Interest expense | - | - | ||
| Net loss | -565,708 | -56,254 | ||
| Comprehensive loss | -565,897 | -56,063 | ||
| Basic (in dollars per share) | -0.76 | -0.08 | ||
| Basic (in shares) | 742,615,007 | 726,656,045 | ||
| Diluted (in dollars per share) | -0.76 | -0.08 | ||
| Diluted (in shares) | 742,615,007 | 726,656,045 | ||